52 results about "Inhalation preparations" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a beclomethasone propionate suspension for inhalation and a preparation method thereof. The beclomethasone propionate suspension for inhalation comprises beclomethasone propionate, a suspending stabilizer and a propellant, and the preparation method comprises the steps of raw material crushing, suspending stabilizer pretreatment, dynamic circulating temperature control mixing, high-pressure homogenization and the like. The settling volume ratio of the suspension is obviously superior to that in the prior art. The preparation provided by the invention has excellent physical and chemical stability and loose storage conditions, and provides a safe and efficient inhalation preparation choice for the treatment of respiratory diseases.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

1. Name of the designed product: environmental simulation box. 2. Use of the designed product: integrated control equipment for environmental parameters (temperature, humidity, static electricity) in the process of testing inhalation preparations. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The application relates to the technical field of pharmaceutical preparation mixing processes, in particular to a stirring device and a high-speed centrifugal device adopting the stirring device, which comprises a stirring paddle and a directional rotor, the stirring paddle and the directional rotor are coaxially and oppositely arranged, and are used for providing opposite shearing forces when rotating. Compared with the prior art, the application has the advantages that when two or more materials with large particle size difference and large proportion difference are mixed, the materials can reach a uniform and stable state in a short time under the action of high shearing force, the RSD value of content detection of random sampling in the tank is at a low level, and the mixed materials can meet the tanking requirements of powder for inhalation preparations.

The invention belongs to the technical field of veterinary traditional Chinese medicine preparations, and particularly relates to a veterinary traditional Chinese medicine compound aerosol inhalation preparation which is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process. The raw material medicines comprise, by weight, 15-30 parts of honeysuckle, 12-25 parts of fructus forsythiae, 10-20 parts of radix isatidis, 8-18 parts of platycodon grandiflorum, 6-15 parts of mint, 5-12 parts of liquorice, 6-14 parts of almond, 8-16 parts of folium mori, 10-22 parts of chrysanthemum and 8-18 parts of scutellaria baicalensis; the requirements of the raw material medicines are as follows: the honeysuckle is a dry flower bud or a flower with initial blooming of a honeysuckle plant, and is dried at low temperature, and the water content is 8-12%; the traditional Chinese medicine composition is prepared from traditional Chinese medicines with the effects of clearing away heat and toxic materials, ventilating the lung, relieving cough, relieving sore throat and diminishing swelling as raw materials through scientific compatibility and a specific process, has the advantages of high targeting property, quick response, definite curative effect, small toxic and side effects, difficulty in drug resistance generation and the like, is excellent in atomization performance, is suitable for group administration, and can effectively solve the problem of prevention and treatment of respiratory diseases of livestock and poultry.

The invention relates to preparations for inhalation and to methods for preventing or treating equine asthma in horses, wherein the preparation contains a vasoactive intestinal peptide (VIP) receptor agonist, in particular aviptadil.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non-pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

The present invention relates to a dry powder composition for an inhalation formulation comprising formoterol or a pharmaceutically acceptable salt thereof, a tiotropium bromide anhydride and a pharmaceutically acceptable carrier. The synthesis methods of the formoterol and the tiotropium bromide are respectively realized through specific chemical reaction steps, and finally high-purity active ingredients are obtained. The weight ratio of the active ingredients to the carrier in the composition is 1: (1-15): (50-50000), and the carrier can be selected from lactose, cane sugar, mannitol or amino acid and the like. The preparation method comprises the following steps: micronizing, mixing, filling into hollow capsules, and finally preparing a finished product through aluminum-plastic packaging. The composition disclosed by the invention has good chemical stability and high inhalation efficiency, can be kept for more than two years at normal temperature, and is accurately and uniformly administered in a targeted lung through a dry powder inhalation device, so that formoterol and tiotropium bromide synergistically play a role in relaxing bronchial smooth muscles, and clinical requirements are met.

The invention belongs to the technical field of inhalation preparations and pulmonary drug delivery, and particularly relates to an atomization preparation for vitamin K inhalation drug delivery and preparation and application thereof. According to the preparation, dipalmitoyl phosphatidylcholine, cholesterol and optional anionic phospholipid are adopted to construct a bionic lung surface activity liposome skeleton LA1, an MK-7 organic phase is intercalated into a liposome double-layer hydrophobic area under the condition of controlling temperature and an energy path, and a continuous phase containing sodium chloride, propylene glycol and a pH regulator is matched to form an isotonic near-neutral environment; a neutral oil phase, a fat-soluble antioxidant, an optional metal chelating agent and a viscosity modifier can be introduced to synergistically optimize the atomization performance. The apparent viscosity of the prepared atomization preparation at 25 DEG C is 1.0-2.5 mPa.s, the osmotic pressure is 280-320 mOsm / kg, the average particle size of lipidosome Z is 80-150 nm, the PDI is not larger than 0.25, the mass median diameter of fog drops atomized by a vibration net type atomizer is 2.0-3.0 microns, the fine particle fraction is not smaller than 60%, and the MK-7 content retention rate is not lower than 90% after 6 months of accelerated storage at 25-40 DEG C.

Provided herein are formulations designed for administration by inhalation, including aqueous based compositions and dry powder compositions. The compositions described herein comprise a nitric oxide (NO) releasing compound, along with one or more additional agents, additives, and / or carriers. The compositions described herein exhibit a heat of decomposition of no greater than 300 J / g. Also described herein are methods of treating respiratory diseases in a subject, comprising administering to the subject an effective amount of a composition described herein.

The present invention relates to the use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, belonging to the field of pharmaceutical technology. The use of fingolimod in the preparation of an oral and nasal inhalation preparation for treating ischemic stroke, the chemical structural formula of the fingolimod is as follows. The present invention adopts the administration method of oral and nasal inhalation, uses fingolimod to treat ischemic stroke, enhances the aggregation of the drug in the lungs, inhibits the migration of pulmonary immune cells to the brain, thereby reducing the inflammation at the stroke site in the brain parenchyma, improving the damage to the nervous system at the stroke site, and promoting the recovery of damaged nerve function. Moreover, the oral and nasal inhalation administration method avoids the side effects such as cardiac conduction block and bradycardia that may be caused when fingolimod is taken orally, and provides a new type of safe and effective administration route for patients with cerebral infarction, especially those with heart disease.

The invention relates to the technical field of inhalation preparations, in particular to an inhalation preparation for relieving or treating upper respiratory tract infection and a preparation method and application thereof. The inhalation preparation comprises an active pharmaceutical ingredient, and the active pharmaceutical ingredient is andrographolide; the inhalation preparation also comprises pharmaceutically acceptable auxiliary materials; the pharmaceutically acceptable auxiliary materials comprise one or more of a solvent, a cosolvent, a propellant, a carrier / diluent, a pH regulator, an antistatic agent and a stabilizer. The prescriptions and the preparation methods of the aerosol, the dry powder inhalation and the spray are suitable for industrial production, and clinical tests prove that the prepared inhalation preparation has a remarkable relieving or treating effect on upper respiratory tract infection.

There is provided inhalable formulations of ruxolitinib, manufacture, and uses thereof.

The invention discloses a preparation method of lactose serving as an inhalation preparation carrier, and belongs to the technical field of pharmaceutical excipients, and the preparation method comprises the following steps: (1) adding superfine lactose seed crystals into ethanol, then dropwise adding a lactose aqueous solution with the mass concentration of 30-60% under the condition of stirring, and continuously stirring for at least 30 minutes after the addition is completed; (2) filtering the solution, and washing a filter cake with ethanol; (3) drying and sieving the filter cake; the lactose prepared by the method is wider in particle size distribution and mainly concentrated in two sections, one section is concentrated in the particle size of fine particles of 1-5 microns, the particle size is close to the particle size of a medicine in an inhalation preparation, and the dispersity of the medicine can be improved; the particle size of the second section is 75-200 microns, the coarse particle can meet the requirement of a third component carrier, and the overall fluidity of lactose is improved.

The invention discloses a medicinal composition of a triple compound inhalation preparation as well as a preparation method and application of the medicinal composition, and relates to the technical field of respiratory system medicinal preparations. According to the pharmaceutical composition, the pharmaceutical composition which is convenient to use and better in effect can be obtained by compounding the ingredients of the pharmaceutical composition, the problem of non-uniform mixing of the ingredients with high dose difference is solved through a step-by-step mixing process, the powder flowability is ensured, the lung delivery efficiency is improved, and the pharmaceutical composition is suitable for clinical application. The medicine can be suitable for maintenance treatment of asthma or chronic obstructive pulmonary disease, and can also prevent acute exacerbation of chronic obstructive pulmonary disease and / or improve the symptom severity of acute exacerbation of chronic obstructive pulmonary disease.

A pressurized inhalation composition includes tiotropium or its pharmaceutically acceptable salt thereof, ethanol, a stabilizer, and a propellant. The ethanol can be in an amount of from about 1% (w / w) to about 10% (w / w) based on the total weight of the pressurized inhalation composition. The composition can be pharmacokinetically bioequivalent to non-pressurized aqueous base inhalation formulation of tiotropium. An inhaler can include the composition contained in a canister fitted with metering valve, and an actuator optionally connected with a dose counter. A process of preparing the pressurized inhalation composition and using the pressurized inhalation composition in the treatment of Asthma and Chronic obstructive pulmonary disease (COPD) in a patient in need thereof by inhalation administration are also described.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

The present disclosure provides an antifungal drug inhalation formulation comprising: crystalline nanoparticles of a triazole-based antifungal drug. The invention further provides a preparation method and application of the antifungal drug inhalation preparation.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

This invention discloses a QL-H008 formulation for treating gliomas, its preparation method, and its application, and also discloses the application of compound QL-H008 in the preparation of drugs for treating gliomas. This invention utilizes an oral-nasal inhalation formulation, inhaling an aerosol containing QL-H008 and pharmaceutically acceptable salts through the mouth and nose to achieve the therapeutic effect on gliomas in situ, demonstrating the promising application of QL-H008 in the treatment of gliomas in situ.

The application discloses an effective component group of Quji-Shell for treating acute lung injury, which comprises naringin, naringin, naringenin 7-O-glucoside, hesperidin and neohesperidin; a preparation method comprises the following steps: (1) crushing Quji-Shell, and soaking and extracting by using ethanol; (2) adding water, and extracting by using ethyl acetate, and performing concentration under reduced pressure; (3) separating and eluting, and combining elution fractions according to chemical component types; and (4) combining chemical component groups Fr.1-4, and obtaining the effective component group of Quji-Shell. The effective component group of Quji-Shell has the advantages of clear chemical composition, high content of anti-inflammatory active components, oral preparation or inhalation preparation which can be developed in clinic, and clear pharmacology and toxicology, and has better medicine property.

The invention discloses an inhalation preparation for treating IPF diseases. The inhalation preparation is an aerosol inhalation liquid preparation, an inhalation aerosol, an inhalation powder aerosol or a soft aerosol. The inhalation preparation comprises an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole and defamilast. A preparation process of an inhalation preparation is introduced into a traditional preparation, active ingredients of a traditional oral preparation are easily damaged in digestive tracts, the bioavailability is low, the liver first-pass effect is achieved, the effect is slow, and the inhalation preparation capable of remarkably improving IPF is prepared. Tests prove that the prepared inhalation preparation can effectively improve the bioavailability and improve the clinical use effect.

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

An inhalation formulation for treating an IPF disease. The inhalation formulation is an aerosol inhalation liquid formulation, an inhalation aerosol, a dry powder inhaler or a soft mist inhaler. The inhalation formulation contains an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole, and difamilast. A preparation process for the inhalation formulation is introduced into a conventional formulation. An active component in a conventional oral formulation is prone to being destroyed in the digestive tract, and has low bioavailability, a liver first pass effect, and a slow onset of action. An inhalation formulation capable of significantly alleviating IPF is prepared. Tests prove that the prepared inhalation formulation can effectively increase the bioavailability, and improve the clinical use effect.

The invention discloses a lung protection function exosome based on resveratrol-astragalus membranaceus-ginseng induction, an inhalation preparation and application, and belongs to the technical field of biology. The exosome is obtained by inducing lung fibroblasts by active ingredients containing resveratrol, an astragalus extract and a ginseng extract and then secreting the lung fibroblasts; wherein the content of astragaloside in the astragalus extract is not less than 2.0%, and the total content of ginsenoside Rg1 and Rb1 in the ginseng extract is not less than 5.0%. The invention also provides a dry powder inhalant or an aerosol inhalation solution containing the exosome. The exosome and the preparation thereof play a lung protection role through multiple mechanisms such as inflammation regulation and control, oxidative stress resistance and repair promotion, can be used for preventing and / or treating various lung injury diseases such as acute lung injury and pneumonia, and have the advantages of good biocompatibility and strong targeting property.

Disclosed is a pharmaceutical composition containing Fudosteine, comprising the following components: a pharmaceutically active ingredient, a pH adjuster, and water. The concentration of Fudosteine in the composition ranges from 20 mg / mL to 200 mg / mL, and the pH value is between 3.0 and 6.0. The pharmaceutically active ingredient is one or more of Fudosteine, a pharmaceutically acceptable salt thereof, and a hydrate thereof. The pharmaceutical composition containing Fudosteine does not comprise an antioxidant, a surfactant, and a metal chelating agent, and can be prepared into an atomized inhalation preparation.

The invention discloses a remote respiratory system disease inhalation medicine management method and a related device, and the method comprises the steps: dynamically constructing a personalized inhalation preparation management path according to clinical data, genome data and past medication history of a patient; a doctor seeing or treatment portrait of a patient is called through a medical care terminal, and multi-modal guidance information is automatically sent to a patient terminal in combination with a time node of a personalized inhalation preparation management path; online card punching recording is completed through the patient end so as to record the inhalation medication condition and physiological data during medication; the inhalation operation video and the clock-in record transmitted by the patient end are evaluated through the medical care end, and the proficiency degree of inhalation operation of the patient is obtained. By continuously monitoring, evaluating and guiding the inhalation technique capability of the patient, the inhalation technique mastering capability of the patient is improved, and the inhalation medication compliance of the patient is improved, so that the inhalation medication management level of the patient with the chronic respiratory airway disease is improved.